Medicines labeled for the same conditions
Alternatives to ceftolozane and tazobactam
14 other medicines are given the same way (intravenous) and in the same FDA class as ceftolozane and tazobactam or labeled mainly for the same use (urinary tract infections); 10 are in its class, beta lactamase inhibitors: cefazolin, cefepime, cefoxitin, ceftriaxone and 6 more; the others include 2 tetracycline-class drugs (FDA labels read October 8, 2026). In the same class, the lowest pharmacy cost is $1.07 per cefazolin 1 g vial (what pharmacies paid in the NADAC survey; strengths differ).
Which medicines are labeled for the same conditions as ceftolozane and tazobactam?
Urinary tract infections lists all 39 medicines labeled for it, by any route. Each row shows the conditions both labels name. They are listed as public records, not as substitutes: whether one can replace another depends on the person and is a prescriber's decision.
| Medicine and FDA class | Shared indication | Generic labelers (intravenous) | Pharmacy cost | Boxed warning | Shortage |
|---|---|---|---|---|---|
| Ceftolozane and tazobactambeta lactamase inhibitor | this medicine | none listed | n/a | No | No current entry |
| Cefazolincephalosporin antibacterial · same class | Urinary tract infections | 7 labelers | $1.07 per vial 1 g vial | No | No current entry |
| Cefepimecephalosporin antibacterial · same class | Urinary tract infections | 8 labelers | n/a | No | A presentation being discontinued |
| Cefoxitincephalosporin antibacterial · same class | Urinary tract infections | 5 labelers | n/a | No | No current entry |
| Ceftriaxonecephalosporin antibacterial · same class | Urinary tract infections | 7 labelers | $1.44 per vial 1 g vial | No | No current entry |
| Cefuroximecephalosporin antibacterial · same class | Urinary tract infections | 2 labelers | n/a | No | No current entry |
| Avibactam and ceftazidimebeta lactamase inhibitor · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Cefepime and zidebactamcephalosporin antibacterial · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Cefiderocolcephalosporin antibacterial · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Cilastatin and imipenem and relebactamrenal dehydropeptidase inhibitor · same class | Urinary tract infections | none listed | n/a | No | A presentation being discontinued |
| Meropenem and vaborbactampenem antibacterial · same class | Urinary tract infections | none listed | n/a | No | No current entry |
| Doxycyclinetetracycline-class drug | Urinary tract infections | 20 labelers | n/a | No | A presentation being discontinued |
| Plazomicin | Urinary tract infections | none listed | n/a | Yes | No current entry |
| Fosfomycin | Urinary tract infections | none listed | n/a | No | No current entry |
| Minocyclinetetracycline-class drug | Urinary tract infections | none listed | n/a | No | No current entry |
Source: FDA drug labels (indications) via openFDA; FDA NDC Directory; CMS NADAC of October 7, 2026; FDA Drug Shortage Database (FDA files October 8, 2026)
What do pharmacies pay for each?
The headline NADAC price per unit of each medicine's most widely listed form; strengths differ, so compare like with like on each record.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What next?
- Ceftolozane and tazobactam: the full record
- label, generics, price, shortages, recalls